docetaxel anhydrous has been researched along with B-Cell Chronic Lymphocytic Leukemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aberg, M; Aleskog, A; Gustafsson, MG; Kanduri, M; Lindhagen, E; Norberg, M; Nygren, P; Rickardson, L; Rosenquist, R; Tobin, G | 1 |
1 other study(ies) available for docetaxel anhydrous and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cells in vitro, as single agent and in drug combination.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cisplatin; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Sirolimus; Taxoids; Tumor Cells, Cultured; Vincristine | 2008 |